Valvular heart disease in pergolide-treated Parkinson's disease

Canadian Journal of Neurological Sciences

Volumn 33, Issue 1, 2006, Pages 111-113

  Scozzafava, James ^a   Takahashi, Jennifer ^a   Johnston, Wendy ^a   Puttagunta, Lakshmi ^a   Martin, W R Wayne ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GLENROSE REHABILITATION HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; LEVODOPA; PERGOLIDE;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART MURMUR; HUMAN; LUNG EDEMA; MEDICAL ASSESSMENT; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

EID: 33645378754     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100004819     Document Type: Article

References (11)

1. Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med. 1966;274:359-68.
2. Misch KA. Development of heart valve lesions during methysergide therapy. Br Med J. 1974;2:365-6.
3. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337:581-8.
4. Khan MA, Herzog CA, St. Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998;339:713-8.
5. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000;57:75-81.
6. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002;10:334-6.
7. Pritchett A, Morrison J, Edwards W, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002;77:1280-6.
8. Van Camp G, Flamez A, Cosyns B, et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology. 2003;61:859-61.
9. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-83.
10. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology. 2004; 63:301-4.
11. Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacology. 1994;33:275-317.